{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Yescarta&page=2", "query": { "intervention": "Yescarta", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Yescarta&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T11:35:09.339Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02926833", "title": "Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "KTE-C19", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2016-09-29", "completion_date": "2023-01-12", "has_results": true, "last_update_posted_date": "2024-03-06", "last_synced_at": "2026-09-25T11:35:09.339Z", "location_count": 5, "location_summary": "Duarte, California • Palo Alto, California • Tampa, Florida + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02926833" }, { "nct_id": "NCT03153462", "title": "Axicabtagene Ciloleucel Expanded Access Study", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Relapsed/Refractory Diffuse Large B Cell Lymphoma", "Relapsed/Refractory Primary Mediastinal B Cell Lymphoma", "Relapsed/Refractory Transformed Follicular Lymphoma", "Relapsed/Refractory High-Grade B-Cell Lymphoma" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2023-11-08", "last_synced_at": "2026-09-25T11:35:09.339Z", "location_count": 15, "location_summary": "Duarte, California • Stanford, California • Miami, Florida + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03153462" }, { "nct_id": "NCT05459571", "title": "Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed or Refractory Large B-cell Lymphoma" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2022-08-09", "completion_date": "2025-11-24", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-09-25T11:35:09.339Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05459571" }, { "nct_id": "NCT04314843", "title": "Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Large B-cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Lenzilumab", "type": "BIOLOGICAL" }, { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-05-26", "completion_date": "2022-07-27", "has_results": true, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-09-25T11:35:09.339Z", "location_count": 10, "location_summary": "Palo Alto, California • Tampa, Florida • Evanston, Illinois + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04314843" }, { "nct_id": "NCT05776160", "title": "Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Large B-cell Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-09-25T11:35:09.339Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05776160" }, { "nct_id": "NCT04432506", "title": "Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent High Grade B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2020-07-27", "completion_date": "2024-05-28", "has_results": true, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-09-25T11:35:09.339Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04432506" }, { "nct_id": "NCT03761056", "title": "Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Lymphoma" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2019-01-29", "completion_date": "2023-10-12", "has_results": true, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-09-25T11:35:09.339Z", "location_count": 5, "location_summary": "Gilbert, Arizona • Duarte, California • Tampa, Florida + 2 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03761056" }, { "nct_id": "NCT05757219", "title": "Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Chimeric antigen receptor (CAR) T-cell therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2023-05-19", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-25T11:35:09.339Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05757219" }, { "nct_id": "NCT02348216", "title": "Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Diffuse Large B Cell Lymphoma (DLBCL)", "Relapsed Diffuse Large B-Cell Lymphoma", "Transformed Follicular Lymphoma (TFL)", "Primary Mediastinal B-cell Lymphoma (PMBCL)", "High Grade B-cell Lymphoma (HGBCL)" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "High-dose methylprednisolone", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 307, "start_date": "2015-04-21", "completion_date": "2023-07-27", "has_results": true, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-09-25T11:35:09.339Z", "location_count": 23, "location_summary": "Gilbert, Arizona • Duarte, California • La Jolla, California + 19 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02348216" }, { "nct_id": "NCT03954106", "title": "A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "DLBCL", "Neurotoxicity Syndromes" ], "interventions": [ { "name": "Defibrotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2019-10-04", "completion_date": "2020-09-30", "has_results": true, "last_update_posted_date": "2021-12-09", "last_synced_at": "2026-09-25T11:35:09.339Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03954106" } ] }